- Home
- ZION vs ROIV Comparison
ZION vs ROIV Comparison
Compare ZION & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZION
- ROIV
- Stock Information
- Founded
- ZION 1873
- ROIV 2014
- Country
- ZION United States
- ROIV United Kingdom
- Employees
- ZION N/A
- ROIV N/A
- Industry
- ZION Major Banks
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- ZION Finance
- ROIV Health Care
- Exchange
- ZION Nasdaq
- ROIV Nasdaq
- Market Cap
- ZION 8.6B
- ROIV 8.4B
- IPO Year
- ZION N/A
- ROIV N/A
- Fundamental
- Price
- ZION $59.03
- ROIV $11.27
- Analyst Decision
- ZION Hold
- ROIV Strong Buy
- Analyst Count
- ZION 19
- ROIV 8
- Target Price
- ZION $57.06
- ROIV $17.93
- AVG Volume (30 Days)
- ZION 1.4M
- ROIV 5.1M
- Earning Date
- ZION 01-21-2025
- ROIV 02-11-2025
- Dividend Yield
- ZION 2.92%
- ROIV N/A
- EPS Growth
- ZION N/A
- ROIV N/A
- EPS
- ZION 4.39
- ROIV 5.89
- Revenue
- ZION $3,010,000,000.00
- ROIV $129,128,999.00
- Revenue This Year
- ZION N/A
- ROIV $15.98
- Revenue Next Year
- ZION $3.73
- ROIV N/A
- P/E Ratio
- ZION $13.46
- ROIV $1.91
- Revenue Growth
- ZION N/A
- ROIV 145.68
- 52 Week Low
- ZION $37.76
- ROIV $9.69
- 52 Week High
- ZION $63.22
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- ZION 62.38
- ROIV 46.46
- Support Level
- ZION $56.35
- ROIV $10.89
- Resistance Level
- ZION $58.91
- ROIV $11.26
- Average True Range (ATR)
- ZION 1.40
- ROIV 0.36
- MACD
- ZION 0.56
- ROIV -0.02
- Stochastic Oscillator
- ZION 98.89
- ROIV 47.75
About ZION Zions Bancorporation N.A.
Zions Bancorporation is a regional us bank with core operations that span 11 states. The bank is headquartered in Salt Lake City and does business primarily in the Western and Southwestern United States. Zions primarily focuses on providing banking services to small and midsize businesses, with the bulk of its loans focused on commercial and commercial real estate lending.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.